Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03064867 · ClinicalTrials.gov registry record · Phase 1

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 study of Diffuse Large B Cell Lymphoma, sponsored by Molly Gallogly.

Active
Registry status
Phase 1
Development phase
65
Enrollment target
3
Study locations

NCT03064867 is a Phase 1 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Molly Gallogly. The registered enrollment target is 65 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03064867, a Phase 1 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Molly Gallogly.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
65 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the correct dose and safety of adding a new cancer drug, venetoclax, to a standard combination of chemotherapy drugs as a second treatment for relapsed/refractory DLBCL. In this study, venetoclax will be added to RICE (rituximab, ifosfamide, carboplatin, etoposide), a common set to cancer drugs used as a second line treatment for relapsed/refractory DLBCL. Venetoclax, is a new targeted anti-cancer drug, which works by mimicking a particular protein produced by the tumor and interrupting its normal processes, ultimately causing the tumor cells to die. Adding venetoclax to the standard RICE regimen is believed to increase the chance of getting cancer into remission. Venetoclax is experimental because it is not approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory DLBCL. Venetoclax has been FDA approved for use in patients with chronic lymphocytic leukemia (CLL).

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Venetoclax
  • DRUG Carboplatin
  • DRUG Rituximab
  • DRUG Etoposide
  • DRUG Ifosfamide

Study Locations (3)

Ohio

  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland

Missouri

  • Washington University School of Medicine, Siteman Cancer Center - St Louis

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2017-06-26
Est. Completion 2023-08-12
Phase Phase 1

Sponsor

Molly Gallogly

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03064867

The ClinicalTrials.gov registry entry for NCT03064867 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (70% lower). The listed sponsor is Molly Gallogly, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.

NCT03064867 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Missouri.

Frequently Asked Questions

What is clinical trial NCT03064867 about?

NCT03064867 is a clinical study titled "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma". The purpose of this study is to determine the correct dose and safety of adding a new cancer drug, venetoclax, to a standard combination of chemotherapy drugs as a second treatment for relapsed/refractory DLBCL. In this study, venetoclax will be added to RICE (rituximab, ifosfamide, carboplatin, eto...

What is the current status of trial NCT03064867?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2017-06-26. Estimated completion is 2023-08-12.

What conditions does trial NCT03064867 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT03064867?

The interventions under investigation include: Venetoclax (DRUG), Carboplatin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Ifosfamide (DRUG).

Who is sponsoring clinical trial NCT03064867?

This trial is sponsored by Molly Gallogly, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03064867 being conducted?

This trial has 3 study locations across Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.